Industry News

In a phase 3 trial, Columvi plus chemo improved survival rates for patients with relapsed or refractory diffuse large B-cell lymphoma

Fabhalta heads towards another indication with a phase 3 win in rare kidney disease

The UK-based biotech received notice that the 2021 deal will be terminated in 180 days

The review began in July 2023, after two patients in Iceland reported adverse events

The cell culture facility expansion will add large-scale production capacity as well as generate an additional 680 jobs by 2031

The judge said Lilly was attempting to use state laws to enforce federal regulations, which is the responsibility of the FDA

Key to the deal is Alpine’s lead molecule, a dual BAFF/APRIL antagonist in phase 3 trials for kidney disease

The deal, which could reach $1.01 billion, gives Novartis access to a potential first-in-class prostate cancer treatment

The five-year deal aims to improve Novo's drug production and advance scalable manufacturing tech

Novartis plans to cut up to 680 jobs in its drug development unit

After withdrawing the BLA for its ALS candidate, BrainStorm will launch a phase 3b trial this year

Abceutics focuses on payload-binding selectivity enhancers

The recent approval makes Enhertu the first tumor-agnostic HER2-directed therapy

The drugmaker shares promising interim results regarding KarXT's long-term efficacy

In a play to better its cardio health offerings, J&J will pick up a medical device maker active in CAD and PAD

The potential $1.4 billion deal gives Merck KGaA access to Caris' proprietary technologies to develop novel cancer ADCs

A decade after its European launch, Zevtera is now approved for three indications in the U.S.

The decision comes after Relyvrio failed to show benefit in a phase 3 trial

The deal will go through a court-structured 363 sale process, where Merz will serve as the "stalking horse" bidder

The acquisition grants Genmab access to three clinical-stage drugs and ProfoundBio’s ADC technology

In a deal that could reach $900 million, Ipsen will pick up a preclinical ROR1 ADC asset

The program is once again paused after a patient experienced temporary health issues

Voydeya is approved as an add-on therapy to the standard-of-care for paroxysmal nocturnal hemoglobinuria

The BLA for a subcutaneous maintenance dose is delayed 60 days while the partners await Fast Track designation

The potential first-in-class drug targets the most common genetic cause of renal failure

Zeposia failed to meet endpoints in a phase 3 trial of patients with moderate to severe active Crohn’s disease

In a deal that could reach $648 million, Gilead bets on a phase 1 tumor-activated IL-12 program

Vadadustat initially faced rejection in 2022, followed by an additional CRL in 2023

With Moderna about to file its seasonal flu vaccine with regulators, Blackstone backs its mRNA tech

The news follows shortly after the drugmaker announced major layoffs at its German facility